St. Francis Hospital Evaluates Innovative Device That May Help Patients Avoid Open-Heart Surgery
ROSLYN, N.Y., April 10, 2007 – St. Francis Hospital, The Heart Center, is the only hospital on Long Island treating patients in a clinical study of a new investigational device to treat mitral regurgitation (MR)--the most common type of heart valve insufficiency--using a cardiac catheterization technique.
St. Francis is one of 34 medical centers in North America evaluating the safety and effectiveness of this percutaneous (through the skin) procedure as part of a Phase II, prospective, randomized, controlled study in patients with moderate to severe or severe MR, as compared to open surgical repair or replacement.
The percutaneous mitral repair procedure uses the MitraClip™ device (made by Evalve, Inc., Menlo Park, CA) to bring the leaflets (the “swinging doors”) of the valve together, helping it to close properly. The procedure is performed by interventional cardiologists in the cardiac catheterization laboratory utilizing general anesthesia. In addition to improving blood flow through the heart, the procedure may also relieve symptoms such as fatigue and shortness of breath that often affect patients with significant MR.
Cardiologist Andrew Berke, M.D. has performed the procedure at St. Francis Hospital. So far, over 160 patients have undergone the procedure as part of the EVEREST studies.
An estimated 4 million people nationwide suffer from significant MR, the most common type of heart valve insufficiency. In these patients, blood leaks backward through the mitral valve with each heartbeat, causing the heart to work harder to circulate oxygenated blood to the rest of the body.
There are no medications that specifically treat or cure MR, though some patients receive drugs to manage the symptoms. Both the American Heart Association and the American College of Cardiology recommend open-heart surgery to repair or replace the mitral valve for patients who suffer from moderate to severe or severe MR. However, only 20 percent of these patients, or approximately 50,000, undergo surgery each year.
If left untreated, valve insufficiency can lead to atrial fibrillation, heart muscle dysfunction, symptoms of congestive heart failure (CHF), and an increased risk of sudden death. Improved treatment options, such as the MitraClip device, can reduce the potential for developing CHF and may improve the quality of life for patients currently suffering from CHF.
For more information about mitral regurgitation or to find out if you may qualify to participate in the EVEREST II study, call toll free 1-877-MY-MR-FIX, 877-696-7349 or visit www.mitralregurgitation.org.
###
About St. Francis Hospital
St. Francis Hospital, The Heart Center is New York State’s only specialty designated cardiac center and is the busiest heart center in the Northeast. A recognized leader in the diagnosis, treatment and prevention of cardiac disease, St. Francis Hospital performs more cardiac surgery and interventional cardiac procedures than any other hospital in New York State. A leader in cardiovascular care for more than 50 years, St. Francis Hospital is a member of Catholic Health Services of Long Island (CHSLI). Contact us at 1.888.HEART.NY or visit us at www.stfrancisheartcenter.com.
Contact:
Paul Barry, 516-705-6657, paul.barry@chsli.org
Rosemary Gomez, 516-705-6656, rosemary.gomez@chsli.org